MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 2|浏览21

暂无评分

摘要

Magrolimab+azacitidine was well tolerated, with promising efficacy in patients with untreated HR MDS, including those with TP53-mutated and -wild-type disease. A Ph3 trial of magrolimab/placebo+azacitidine (ENHANCE; NCT04313881) is ongoing.

查看译文

关键词

MDS,myelodysplastic syndromes,magrolimab,azacitidine,CD47,TP53, Phase I

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要